COMPANY PROFILE

Cholestech

Explore full profile

Rapid point-of-care diagnostics enhancing patient care with immediate results and comprehensive support

San Diego, United StatesFounded 1988Health

Valuation $100–250M Last recorded · 1991

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Cholestech

Abbott's Global Point of Care division specializes in rapid diagnostic testing solutions, catering primarily to healthcare professionals and institutions. Operating in the medical diagnostics market, the business focuses on providing point-of-care testing (POCT) systems that deliver quick and reliable results, crucial for timely medical decision-making. Their product offerings include the i-STAT system, which allows for wireless diagnostic testing and seamless integration with electronic medical records (EMR), and the Cholestech System, which aids in heart disease counseling during office visits. Abbott's business model revolves around the sale of diagnostic equipment and consumables, generating revenue through product sales and ongoing technical support services. The company empowers healthcare professionals with educational resources through platforms like myPOCacademy, ensuring they stay informed about the latest advancements in POCT. Abbott's solutions are designed to improve patient outcomes by enabling faster diagnosis and treatment, although product availability may vary by region.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 1988
Headquarters: San Diego, United States
Employees: 62
Open positions: None listed
Dealroom signal: 30.8/100
Industry: Health
Sector: Health
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Feb 1991	$24M	$96M	Undisclosed	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Cholestech website traffic

Latest recorded traffic for Cholestech is 620K monthly website visits, up 106.7% over the last three months. Cholestech's team declined 17.3% over the past year.

Latest monthly visits620K 3-month web change+106.7% 1-year team growth-17.3%

Monthly website visitsOct 2022–Jan 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CUCuroTisDevelops implantable regenerative grafts that stimulate the body to grow functional vascular tissue for patients requiring vascular access, such as those undergoing dialysis	Maastricht, Netherlands	Operational	6	—	$14M
AUAutodisplayAutodisplay Technology is Autodisplay Biotech’s first generation cell surface display technology	Düsseldorf, Germany	Operational
ITInCarda TherapeuticsA clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route	Palo Alto, United States	Operational
TTThelial TechnologiesDedicated to improving the treatment of diseases where biological barrier defects are a primary cause	Lisbon, Portugal	Closed
HYHybrigenicsBioinformatics platforms to identify, validate, and inhibit protein interactions to develop therapeutics for cancer	Paris, France	Operational
ETEcrins TherapeuticsInnovative oncology drug discovery and development using proprietary platforms	Böblingen, Germany	Operational
PAPathoQuestPathoQuest is a biotechnology company identifying pathogens through High Throughput Sequencing (HTS).	Paris, France	Acquired
NONovoCureNovocure is a global oncology company pioneering a novel therapy for solid tumors. Patient images reflect patient(s) health status when photographed	Root, Switzerland	Operational